Arsenal Biosciences, Inc.

ArsenalBio Shifts Strategic Focus to In Vivo CAR T Cell Therapies, Expanding into Autoimmunity

- ArsenalBio announced a strategic shift to focus on developing in vivo CAR T cell therapies, leveraging its investment in T cell biology, synthetic biology, computation, and cell engineering. - The company will expand beyond solid tumors into a broader range of diseases, including hematologic malignancies and autoimmune diseases. - The transition involves a substantial workforce reduction, with a core team remaining to advance the in vivo strategy and evaluate strategic opportunities. - Clinical data from ArsenalBio's autologous cell therapy programs for solid tumors will be presented at a future medical meeting.